{"title": "Field trials for testing of white-nose syndrome vaccine candidates Active", "author": null, "url": "https://www.usgs.gov/centers/nwhc/science/field-trials-testing-white-nose-syndrome-vaccine-candidates", "hostname": "usgs.gov", "description": "White-nose syndrome (WNS), caused by the fungus Pseudogymnoascus destructans (Pd), continues to decimate bat populations in North America, and efforts to develop treatment options have intensified. One potential method for controlling WNS is vaccination of bats with specific antigens to elicit a protective immune response.", "sitename": "U.S. Geological Survey", "date": "2021-10-26", "cleaned_text": "fungus Pseudogymnoascus destructans (Pd), continues to decimate bat populations in North America, and efforts to develop treatment options have intensified. One potential method for controlling WNS is vaccination of bats with specific antigens to elicit a protective immune response. We developed several potential vaccine candidates for WNS using raccoon pox virus as a vaccine vector and demonstrated in a laboratory setting that orally immunized bats survived Pd challenge through a 120-day hibernation period at a higher rate than controls that received a placebo ( [Rocke, et al. 2019](https://www.nature.com/articles/s41598-019-43210-w.epdf?author_access_token=yYj1JPVPb57Qn1b27l1gy9RgN0jAjWel9jnR3ZoTv0OVAcG24o0yW14y6fzrEUBTNS5AIEw_OIsHGnhudyBhFaY39eQpnFMBLKgHhABLnx-MOkSKlLbpDAd7eHBCda05tO_4HClmbZQ-QWr5z8N_rg%3D%3D)). Two vaccine candidates were registered and authorized for field use by the USDA Center for Veterinary Biologics in September 2019, and a limited field trial was immediately initiated at two hibernacula in Wisconsin to assess vaccine efficacy under field conditions. Little brown bats (Myotis lucifigus) were collected within hibernacula during fall swarm (mid- to late-September) and orally administered vaccine or placebo by hand. Data demonstrated that bats treated with one of two tested vaccine constructs had significantly lowered Pd pathogen loads compared to controls; also, both higher and later rates of emergence were observed among vaccinated bats compared to non-vaccinated bats. Further field studies have been initiated to study the efficacy of the vaccines in various conditions. - To determine effect of age on vaccination, juveniles and adult females were vaccinated at maternity roosts in the summers of 2020 and 2021. - The effect of timing is also being investigated with vaccinations occurring during fall swarm. - Additional field studies were initiated in multiple states with varying Pd prevalence (endemic, emerging, and pre-arrival) and in additional bat species, such as cave myotis (Myotis velifer) in Texas and Yuma myotis (Myotis yumanensis) in Washington and Idaho. - Additional laboratory and field studies were conducted to select and optimize the best medium for application - by hand, with a spray device, or application to maternity roost structures - and determine the appropriate dose of vaccine required for topical application. Below are other science projects associated with this project. [ White-Nose Syndrome Surveillance ](/centers/nwhc/science/white-nose-syndrome-surveillance) [ White-Nose Syndrome ](/centers/nwhc/science/white-nose-syndrome) Below are multimedia items associated with this project. Below are publications associated with this project. [ Fluorescent biomarkers demonstrate prospects for spreadable vaccines to control disease transmission in wild bats ](/publications/fluorescent-biomarkers-demonstrate-prospects-spreadable-vaccines-control-disease) [ Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus) ](/publications/virally-vectored-vaccine-candidates-against-white-nose-syndrome-induce-anti-fungal) Below are data or web applications associated with this project. [ White-Nose Syndrome Occurrence Map ](/tools/white-nose-syndrome-occurrence-map) View current and archived maps of white-nose syndrome occurrence by county/district. Below are news stories associated with this project. [Overview](#overview) White-nose syndrome (WNS), caused by the fungus Pseudogymnoascus destructans (Pd), continues to decimate bat populations in North America, and efforts to develop treatment options have intensified. One potential method for controlling WNS is vaccination of bats with specific antigens to elicit a protective immune response. We developed several potential vaccine candidates for WNS using raccoon pox virus as a vaccine vector and demonstrated in a laboratory setting that orally immunized bats survived Pd challenge through a 120-day hibernation period at a higher rate than controls that received a placebo ( [Rocke, et al. 2019](https://www.nature.com/articles/s41598-019-43210-w.epdf?author_access_token=yYj1JPVPb57Qn1b27l1gy9RgN0jAjWel9jnR3ZoTv0OVAcG24o0yW14y6fzrEUBTNS5AIEw_OIsHGnhudyBhFaY39eQpnFMBLKgHhABLnx-MOkSKlLbpDAd7eHBCda05tO_4HClmbZQ-QWr5z8N_rg%3D%3D)). Two vaccine candidates were registered and authorized for field use by the USDA Center for Veterinary Biologics in September 2019, and a limited field trial was immediately initiated at two hibernacula in Wisconsin to assess vaccine efficacy under field conditions. Little brown bats (Myotis lucifigus) were collected within hibernacula during fall swarm (mid- to late-September) and orally administered vaccine or placebo by hand. Data demonstrated that bats treated with one of two tested vaccine constructs had significantly lowered Pd pathogen loads compared to controls; also, both higher and later rates of emergence were observed among vaccinated bats compared to non-vaccinated bats. Further field studies have been initiated to study the efficacy of the vaccines in various conditions. - To determine effect of age on vaccination, juveniles and adult females were vaccinated at maternity roosts in the summers of 2020 and 2021. - The effect of timing is also being investigated with vaccinations occurring during fall swarm. - Additional field studies were initiated in multiple states with varying Pd prevalence (endemic, emerging, and pre-arrival) and in additional bat species, such as cave myotis (Myotis velifer) in Texas and Yuma myotis (Myotis yumanensis) in Washington and Idaho. - Additional laboratory and field studies were conducted to select and optimize the best medium for application - by hand, with a spray device, or application to maternity roost structures - and determine the appropriate dose of vaccine required for topical application. [Science](#science) Below are other science projects associated with this project. [White-Nose Syndrome Surveillance](/centers/nwhc/science/white-nose-syndrome-surveillance)The USGS National Wildlife Health Center (NWHC) assists State, Federal, and Tribal wildlife agencies nationwide with early detection of Pseudogymnoascus destructans (Pd), and addresses specific research priorities identified by partners in conjunction with the White-Nose Syndrome National Plan. [White-Nose Syndrome](/centers/nwhc/science/white-nose-syndrome)White-nose syndrome (WNS) is an emergent disease of hibernating bats that has spread from the northeastern across United States at an alarming rate. [Multimedia](#multimedia) Below are multimedia items associated with this project. [Publications](#publications) Below are publications associated with this project. [Fluorescent biomarkers demonstrate prospects for spreadable vaccines to control disease transmission in wild bats](/publications/fluorescent-biomarkers-demonstrate-prospects-spreadable-vaccines-control-disease)Vaccines that autonomously transfer among individuals have been proposed as a strategy to control infectious diseases within inaccessible wildlife populations. However, rates of vaccine spread and epidemiological efficacy in real-world systems remain elusive. Here, we investigate whether topical vaccines that transfer among individuals through social contacts can control vampire bat rabies\u2014a medicAuthorsKevin M. Bakker, Tonie E. Rocke, Jorge E. Osorio, Rachel C. Abbott, Carlos Tello, Jorge Carerra, William Valderrama, Carlos Shiva, Nestor Falcon, Daniel G. Streicker [Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus)](/publications/virally-vectored-vaccine-candidates-against-white-nose-syndrome-induce-anti-fungal)White-nose syndrome (WNS) caused by the fungus, Pseudogymnoascus destructans (Pd) has killed millions of North American hibernating bats. Currently, methods to prevent the disease are limited. We conducted two trials to assess potential WNS vaccine candidates in wild-caught Myotis lucifugus. In a pilot study, we immunized bats with one of four vaccine treatments or phosphate-buffered (PBS)AuthorsTonie E. Rocke, Brock C. Abbott, Marcos Isidoro Ayza, Hannah E. Dobson, Lucas dos Santos Dias, Kevin Galles, Julia S. Lankton, Elizabeth Falendysz, Jeffrey M. Lorch, J. Scott Fites, Jaime Lopera-Madrid, Bruce Klein, Jorge E. Osorio, J. Paul White [Web Tools](#web-tools) Below are data or web applications associated with this project. [White-Nose Syndrome Occurrence Map](/tools/white-nose-syndrome-occurrence-map) View current and archived maps of white-nose syndrome occurrence by county/district. [News](#news) Below are news stories associated with this project. "}